Sigma Advanced Systems Limited has completed the sale of its entire 36.52 percent equity stake in Extrovis AG, a pharmaceutical company based in Switzerland, for $15 million (approximately ₹137.61 crore).
The company indicated that this divestment enhances its financial flexibility, allowing for an accelerated expansion of its aerospace and defense operations. “The divestment is part of Sigma’s ongoing portfolio rationalization strategy. We have transitioned into a pure-play aerospace and defense platform,” a company spokesperson stated.
Sunil Kalidindi, CEO of Sigma Advanced Systems, elaborated on the strategic nature of this transaction, noting that it sharpens Sigma’s focus as a global aerospace and defense manufacturing entity. He added that the divestment strengthens the company’s balance sheet, providing increased flexibility to invest in new capabilities and pursue strategic opportunities, thus supporting the next phase of Sigma’s growth.
Recently, the company also acquired AS Strategic, a defense and space-focused firm based in Delhi with substantial connections in Europe.
In related developments, the Hyderabad-based company secured new orders worth around ₹100 crore from the Ministry of Defence and associated defense public sector units.
Published on April 22, 2026.
